Role of CD4+ regulatory T cells in multiple myeloma
CUKUROVA MEDICAL JOURNAL, vol.42, no.3, pp.546-551, 2017 (ESCI, TRDizin)
- Publication Type: Article / Review
- Volume: 42 Issue: 3
- Publication Date: 2017
- Doi Number: 10.17826/cutf.323972
- Journal Name: CUKUROVA MEDICAL JOURNAL
- Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Page Numbers: pp.546-551
- Keywords: Multiple myeloma, regulatory T cells, PD-1/PDL1-PDL2, B7 FAMILY, EXPRESSION, MEMBER, B7-H1, FOXP3, TRANSPLANTATION, INTERLEUKIN-10, MECHANISMS, PD-L1
- Open Archive Collection: AVESIS Open Access Collection
- Akdeniz University Affiliated: Yes
Abstract
In many studies, regulatory T cell increase is seen both in patients with newly diagnosed multiple myeloma and post chemotherapy patients including autologous stem cell transplants. Multiple myeloma is a malignant plasma cell disease. Regulatory T cells have a role in immune homeostasis from cancer and inflamatory conditions to autoimmune diseases. PD-1 pathway stimulates T cell population towards regulatory T cell development. It has been shown that PDL1 plays an important role in differentiating inducable regulatory T cells. Recently, at least six clinical studies targeting PDL1 or PD-1 on multiple myeloma have been started. In accordance with the current literature, we suggest that patients with myeloma can benefit anti PD-1/PDL1 therapy.